The interactions between PD-1 and PD-L1 of cancer cells inhibit T cell activation by blocking the signaling of T cell receptors through the activation of the mTOR and MAPK pathways, thereby inhibiting Drp1 activation [21]. The gene discussed is DNM1L; the disease is cancer.